Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Elevation Oncology (Nasdaq: ELEV), a company focused on developing selective cancer therapies for solid tumors, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Joseph J. Ferra will engage in a fireside chat on Tuesday, September 10, 2024, at 11:30 am ET.

The event will be accessible via a live webcast, with a replay available afterwards. Interested parties can view the webcast on the Events page of Elevation Oncology's Investor Relations website at https://investors.elevationoncology.com. This presentation offers an opportunity for investors and analysts to gain insights into the company's innovative approach to cancer treatment and its future prospects in the oncology sector.

News Market Reaction

-5.89%

1 alert

-5.89% News Effect

On the day this news was published, ELEV declined 5.89%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the H.C. Wainwright 26^th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET.

A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.

About Elevation Oncology, Inc.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class ADC designed to target Claudin 18.2 and is currently being evaluated in a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit www.ElevationOncology.com.

Elevation Oncology Investor and Media Contact

Hannah Deresiewicz, 212-362-1200
EVP, Managing Director, Precision AQ
hannah.deresiewicz@precisionaq.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302236283.html

SOURCE Elevation Oncology

FAQ

When is Elevation Oncology (ELEV) presenting at the H.C. Wainwright Global Investment Conference?

Elevation Oncology (ELEV) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024, at 11:30 am ET.

Who will be representing Elevation Oncology (ELEV) at the H.C. Wainwright conference?

Joseph J. Ferra, the Chief Executive Officer of Elevation Oncology (ELEV), will be participating in a fireside chat at the H.C. Wainwright conference.

How can I watch Elevation Oncology's (ELEV) presentation at the H.C. Wainwright conference?

A live webcast of Elevation Oncology's (ELEV) presentation will be available on the Events page of the company's Investor Relations website at https://investors.elevationoncology.com.

What is the focus of Elevation Oncology (ELEV) as a company?

Elevation Oncology (ELEV) is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.